Biotech | August 24, 2021
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Shanghai Roche Pharmaceuticals and Shanghai KeChow Pharma, entered into a cooperation agreement to improve market access of Zelboraf in China.
The software enables real-time communication between patients, caregivers, physicians, and pharmacists and each cartridge in the device has a unique, traceable serial number registered to the patient
This brings hope for patients suffering from all types of hernia, as the centre has a replenished armamentarium of technology and techniques to produce a good outcome
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
The government plans to enrol over 50 crore people and empanel more hospitals under the scheme. The scheme provides a cover of Rs 5 lakh per family per year
It is estimated that 300 million men worldwide were affected by ED in 2020, a figure projected to increase to 322 million by 2025. Nearly 30% of these were aged between 40 and 70
It strengthens its presence to over 250 stores
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
Subscribe To Our Newsletter & Stay Updated
